 phase II clinic trial carboplatin infus high-risk acut nonlymphoblast leukemia carboplatin cbdca second-gener platinum drug use continu infus treatment refractori adult leukemia effect continu infus cbdca day patient secondari acut nonlymphocyt leukemia anll previou myelodysplast syndrom treatment-associ anll anll patient first relaps refractori anll patient blastic phase chronic myelogen leukemia bp-cml patient assess respons rate complet remiss cr partial remiss pr median durat postchemotherapi neutropenia day rang therapi toxic hematolog nondose-limit prolong neutropenia sever infect patient outpati patient nausea vomit symptomat hypomagnesemia patient revers ototox substanti antileukem activ unusu extrahematolog toxic cbdca effect second-lin agent treatment anll first-lin treatment regimen